UTHR Q2 2020 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$362M-3.1% YoY

Gross Profit

$336M92.8% margin

Operating Income

$141M38.8% margin

Net Income

$107M29.6% margin

EPS (Diluted)

$2.41

QoQ Revenue Growth

+1.6%

Cash Flow

Operating Cash Flow

$164M

Free Cash Flow

$146M

Stock-Based Comp.

$52M

Balance Sheet

Total Assets

$4.2B

Total Liabilities

$1.1B

Stockholders' Equity

$3.1B

Cash & Equivalents

$685M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$362M	$374M	-3.1%
Gross Profit	$336M	$347M	-3.1%
Operating Income	$141M	$221M	-36.5%
Net Income	$107M	$205M	-47.8%

Revenue Segments

Tyvaso

$119M33%

Remodulin

$119M33%

Orenitram

$75M21%

Unituxin

$29M8%

Adcirca

$19M5%

Geographic Segments

UNITED STATES

$351M97%

European Union And Others

$11M3%